Show simple item record

dc.contributor.advisorYuluğ, Işık
dc.contributor.authorKöseer, Ayşe Sedef
dc.date.accessioned2018-09-14T06:18:25Z
dc.date.available2018-09-14T06:18:25Z
dc.date.copyright2018-08
dc.date.issued2018-09
dc.date.submitted2018-09-03
dc.identifier.urihttp://hdl.handle.net/11693/47873
dc.descriptionCataloged from PDF version of article.en_US
dc.descriptionThesis (M.S.): Bilkent University, Department of Molecular Biology and Genetics, İhsan Doğramacı Bilkent University, 2018.en_US
dc.descriptionIncludes bibliographical references (leaves 63-89).en_US
dc.description.abstractSilecing of tumor suppressor genes via CpG hypermethylation in promoter regions is one of the frequent events occurring in different types of cancers. These genes have the potential as a diagnostic or a prognostic biomarker. Liquid biopsy is a relatively less invasive technique that is used for early diagnosis, therapy response prediction, minimal residual disease detection and real-time monitoring of tumor progression. In this study, a 402 bp region (-286 bp to -80 bp for Section 1, -102 bp to +115 bp for Section 2) located in TAGLN promoter containing 22 CpGs was analyzed in breast cancer patients and healthy donors to evaluate the biomarker potential of TAGLN promoter methylation levels in breast cancer. TAGLN promoter region was significantly hypermethylated in breast cancer patients (77.3%) compared to healthy donors (68.2%). Among differentially methylated CpGs, 6 out of 22 were hypermethylated and one was hypomethylated in breast cancer patients. We also analyzed the relationship between TAGLN promoter methylation levels and the patient's clinicopathological parameters. Analyses revealed that TAGLN promoter is highly methylated in breast cancer patients over 50 years of age compared to the healthy donors in the same age group. TAGLN promoter methylation did not differ as related to various clinicopathological parameters of breast cancer patients. TAGLN promoter methylation levels diagnosed breast cancer patients with 74.45% specificity and 57.58% sensitivity. Additionally, independent of the age group breast cancer patients (131.6 ng) exhibited higher levels of total cfDNA compared to healthy donors (56.4 ng). Pre- and postmenopausal breast cancer patients possessed higher total cfDNA levels compared to pre- and postmenopausal healthy donors. Total cfDNA levels did not differ in various clinicopathological parameters of breast cancer patients; however, total cfDNA levels diagnosed breast cancer patients with 73.33% specificity and 56.72% sensitivity. In summary, breast cancer patient sera can be used to identify the tumor profile, and TAGLN promoter hypermethylation and total cfDNA levels could serve as a diagnostic biomarker in breast cancer.en_US
dc.description.statementofresponsibilityby Ayşe Sedef Köseer.en_US
dc.format.extentxiv, 94 leaves : illustrations, charts (some color) ; 30 cm.en_US
dc.language.isoen_USen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTransgelinen_US
dc.subjectTAGLNen_US
dc.subjectSM22 Alphaen_US
dc.subjectBreast Canceren_US
dc.subjectDNA Methylationen_US
dc.subjectHypermethylationen_US
dc.subjectBiomarkeren_US
dc.subjectDiagnosisen_US
dc.subjectCell-Free Circulating DNAen_US
dc.subjectcfDNAen_US
dc.titleEvaluation of TAGLN as a diagnostic marker in breast canceren_US
dc.title.alternativeMeme kanserinde transgelin geninin tanıyıcı bir belirteç olarak değerlendirilmesien_US
dc.typeThesisen_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.publisherBilkent Universityen_US
dc.description.degreeM.S.en_US
dc.identifier.itemidB158944
dc.embargo.release2019-03-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record